Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis

de Rycke, Leen, Baeten, Dominique, Kruithof, Elli, Van den Bosch, Filip, Veys, Eric M., de Keyser, Filip · 2005 · Arthritis & Rheumatism

Abstract

Objective: To analyze the clinical and biologic correlates of autoantibody induction during longer‐term tumor necrosis factor α (TNFα) blockade with either the monoclonal antibody infliximab or the soluble receptor etanercept. Methods: Thirty‐four patients with spondylarthropathy (SpA) and 59 patients with rheumatoid arthritis (RA) were treated with infliximab for 2 years. Additionally, 20 patients with SpA were treated with etanercept for 1 year. Sera were blindly analyzed for antinuclear antibodies (ANAs), anti–double‐stranded DNA (anti‐dsDNA) antibodies, anti–extractable nuclear antigen (anti‐ENA) antibodies, and antihistone, antinucleosome, and anticardiolipin antibodies (aCL). The anti‐dsDNA antibodies were isotyped. Results: High numbers of infliximab‐treated patients with SpA or RA had newly induced ANAs (61.8% and 40.7%, respectively) and anti‐dsDNA antibodies (70.6% and 49.2%, respectively) after 1 year, but no further increase between year 1 and year 2 was observed. In contrast, induction of ANAs and anti‐dsDNA antibodies was observed only occasionally in the etanercept‐treated patients with SpA (10% of patients each). Isotyping revealed almost exclusively IgM or IgM/IgA anti‐dsDNA antibodies, which disappeared upon interruption of treatment. Neither infliximab nor etanercept induced other lupus‐related reactivities such as anti‐ENA antibodies, antihistone antibodies, or antinucleosome antibodies, and no clinically relevant lupus‐like symptoms were observed. Similarly, infliximab but not etanercept selectively increased IgM but not IgG aCL titers. Conclusion: The prominent ANA and anti‐dsDNA autoantibody response is not a pure class effect of TNFα blockers, is largely restricted to short‐term IgM responses, and is not associated with other serologic or clinical signs of lupus. Similar findings with aCL suggest that modulation of humoral immunity may be a more general feature of infliximab treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.21190

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 172

Metadata

Authors
de Rycke, L., Baeten, D., Kruithof, E., Van den Bosch, F., Veys, E. M., & de Keyser, F.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2005-06-28
Volume
52
Issue
7
Pages
2192-2201
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2077358378
Cited by
172
References
6
FWCI
12.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis. https://app.cochat.ai/papers/10.1002/art.21190
The paper
de Rycke, L., Baeten, D., Kruithof, E., Van den Bosch, F., Veys, E. M., & de Keyser, F. (2005). Infliximab, but not etanercept, induces IgM anti–double‐stranded DNA autoantibodies as main antinuclear reactivity: Biologic and clinical implications in autoimmune arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.21190

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.